Janssen's Incivo to outshine Merck's Victrelis after fast-tracked NICE yes
This article was originally published in Scrip
Executive Summary
Janssen-Cilag's hepatitis C treatment Incivo (telaprevir) looks set to join rival drug Merck & Co's Victrelis (boceprevir) as an NHS treatment option in England and Wales after NICE, the health technology appraisal institute, fast-tracked final draft guidance recommending the drug, just one week after it did the same for fellow protease inhibitor Victrelis. However, analysts expect that sales of Incivo will eventually outstrip sales of Victrelis in the UK, as they have in the US.